- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05878288
Dypsekvensering i kutane plateepitel-Cell-karsinomer (DISCERN)
Omfattende og dyp profilering i kutane plateepitelkarsinomer for å avdekke behandlingseffektivitet hos immunterapibehandlede pasienter
To comprehensively describe the molecular profile of the tumour ecosystem of cutaneous squamous cell carcinoma (CSCC) patients treated with neoadjuvant immunotherapy using single-cell sequencing and bulk genomic profiling.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The purpose of this study is to comprehensively assess the molecular profile of the tumour ecosystem of CSCC patients who receive immunotherapy in the neoadjuvant curative setting, in order to identify molecular mechanisms facilitating treatment response and resistance and to identify molecular markers for disease monitoring. Patients who receive immunotherapy for the neoadjuvant management of CSCC will be invited to participate in this translational research study during their treatment journey to provide tumour tissue (fresh and formal-fixed paraffin-embedded, FFPE) and blood samples before and after exposure to immunotherapy.
This study has primarily a translational research objective with the clinical component conducted as a prospective, single-centre, single-arm, open label study.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Victoria
-
Melbourne, Victoria, Australia, 3000
- Peter MacCallum Cancer Centre
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Stage II to IV (M0) CSCC who are candidates for surgery, but who have an increased risk of recurrence and/or risk of disfigurement or loss of function. Patients with stage III or IV (M0) CSCC of the head/neck, extremity, or trunk are eligible, and patients with stage II CSCC (≥3 cm longest diameter in an aesthetically sensitive region).
-
At least one measurable lesion per RECIST 1.1.
-
Age ≥18 years.
-
Histologically confirmed diagnosis of invasive CSCC.
-
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
-
Anticipated life expectancy >12 weeks.
-
Adequate organ function defined as:
i) Hepatic function:
- Total bilirubin ≤1.5× upper limit of normal (ULN).
- Patients with Gilbert's Disease and total bilirubin up to 3× ULN are eligible.
- Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ≤3× ULN.
- Alkaline phosphatase (ALP) ≤2.5× ULN. ii) Renal function: Serum creatinine ≤2× ULN or estimated creatinine clearance >35 mL/min (according the method of Cockcroft and Gault). iii) Creatinine phosphokinase (CPK) (also known as CK [creatinine kinase]) elevation ≤ grade 2. iv) Bone marrow function:
- Haemoglobin ≥9.0 g/dL.
- Absolute neutrophil count (ANC) ≥1.5 x 109/L.
- Platelet count ≥75 x 109/L.
Exclusion Criteria:
- Active solid malignancy or haematological malignancies including chronic lymphocytic leukaemia, (unless indolent or non-life-threatening) within the last 5 years. For clarity, exceptions include other non-melanoma skin cancer that has undergone potentially curative therapy, or in-situ cervical carcinoma or in-situ prostate cancer with non-detectable prostate specific antigen or any other tumour that has been treated, and the patient is deemed to be in complete remission for at least 2 years prior to enrolment.
- Metastatic disease.
- Steroid use >10mg prednisone per day within 14 days of study drug (except if physiologic replacement).
- Active autoimmune disease requiring active systemic therapy within the last 5 years.
- Interstitial lung disease or pneumonitis requiring systemic therapy in the last 5 years.
- Active infection requiring therapy including human immunodeficiency virus (HIV)-1 or HIV-2 serum antibody, hepatitis B virus (HBV), or hepatitis C virus (HCV), or active tuberculosis.
- Breast-feeding or positive serum pregnancy test consistent with pregnancy (excluding false positives defined as a failure of βHCG doubling in 48 hours) or inability to comply with recommended contraception.
- Receipt of live vaccine (including attenuated) within 30 days of first study treatment.
- Prior transplant recipient (corneal transplant patients are eligible).
- Prior PD-L1/PD-1 inhibitor exposure for the same lesion as enrolment.
- Squamous cell carcinoma of unknown primary (those with presumed clinical assessment of CSCC are eligible).
- Any anticancer treatment other than radiation therapy (such as chemotherapy, targeted systemic therapy, imiquimod, photodynamic therapy), either investigational or standard of care, within 30 days of the initial administration of cemiplimab or planned to occur during the study period.
- History of documented allergic reactions or acute hypersensitivity reaction attributed to antibody treatments.
- Patients with allergy or hypersensitivity to cemiplimab or to any of the excipients must be excluded.
- Institutionalised patients by order of judicial or administrative authority.
- Not willing to comply with all study related procedures, particularly consent for collection of tumour and blood samples and imaging, at all protocol specified time points.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Annen: Cemiplimab
Cemiplimab 350 mg intravenously every 3 weeks for up to 12 weeks (up to 4 doses), or until unacceptable toxicity, disease progression, or withdrawal of consent. |
Cemiplimab 50 mg/mL supplied as a sterile liquid in single-use glass vials.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Rate of successful execution and generation of data from single-cell RNA sequencing and genomic profiling (including whole exome sequencing, RNA sequencing and immunohistochemistry) of CSCC from patients treated with immunotherapy
Tidsramme: At 72 months
|
Generation of analyzable data from single-cell RNA sequencing and genomic profiling |
At 72 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
For å evaluere patologiske responsrater (cPR, mPR definert som <10 % levedyktig svulst og annet).
Tidsramme: Estimert 48 måneder
|
Estimert 48 måneder
|
|
For å evaluere ORR ved hjelp av computertomografi (CT) skanningsavbildning vurdert av RECIST 1.1
Tidsramme: Estimert 48 måneder
|
Estimert 48 måneder
|
|
For å evaluere ORR ved hjelp av computertomografi (CT) skanningsavbildning vurdert av imRECIST
Tidsramme: Estimert 48 måneder
|
Estimert 48 måneder
|
|
For å oppsummere immunrelaterte bivirkninger (AE) > grad 2, AESI, AE > grad 3 og SAE, i henhold til CTCAE v5.0.
Tidsramme: Ved 72 måneder
|
Ved 72 måneder
|
|
For å evaluere DFS-rater.
Tidsramme: Estimert 48 måneder
|
Estimert 48 måneder
|
|
For å evaluere OS-rater.
Tidsramme: Estimert 48 måneder
|
Estimert 48 måneder
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Beskriv om genomiske endringer identifisert i CSCC og TME er detekterbare i cfDNA og fullblod, og om disse korrelerer med behandlingsrespons.
Tidsramme: 72 måneder
|
72 måneder
|
|
|
Beskriv molekylære mekanismer som ligger til grunn for respons på immunterapi i CSCC ved å sammenligne tumor- og TME-profiler fra immunterapirespondere vs non-responders definert ved bruk av patologisk respons og CT-avbildning, for å identifisere antatte prediktive biomarkører.
Tidsramme: 72 måneder
|
72 måneder
|
|
|
To describe any changes in the extent of surgical plans with the use of neoadjuvant immunotherapy, comparing plans at baseline and following neoadjuvant therapy.
Tidsramme: Estimated 48months
|
This outcome will be descriptive. |
Estimated 48months
|
|
Describe molecular mechanisms underlying resistance to immunotherapy in CSCC by comparing tumour and TME profiles from immunotherapy responders vs nonresponders defined using pathological response and CT imaging, to identify putative therapeutic targets.
Tidsramme: 72 months
|
The outcome will be descriptive. |
72 months
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Annette M Lim, MBBS, FRACP, PhD, Peter MacCallum Cancer Centre, Australia
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- HREC/88736/PMCC-2022-326880
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .